Cargando…

Predictive biomarkers for the responsiveness of recurrent glioblastomas to activated killer cell immunotherapy

BACKGROUND: Recurrent glioblastoma multiforme (GBM) is a highly aggressive primary malignant brain tumor that is resistant to existing treatments. Recently, we reported that activated autologous natural killer (NK) cell therapeutics induced a marked increase in survival of some patients with recurre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hwang, Sohyun, Lim, Jaejoon, Kang, Haeyoun, Jeong, Ju-Yeon, Joung, Je-Gun, Heo, Jinhyung, Jung, Daun, Cho, Kyunggi, An, Hee Jung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875464/ https://www.ncbi.nlm.nih.gov/pubmed/36694264 http://dx.doi.org/10.1186/s13578-023-00961-4

Ejemplares similares

Maximal surgical resection and adjuvant surgical technique to prolong the survival of adult patients with thalamic glioblastoma
por: Lim, Jaejoon, et al.
Publicado: (2021)

Epidermoid cyst with unusual magnetic resonance characteristics and spinal extension
por: Lim, Jaejoon, et al.
Publicado: (2015)

The modified lateral supraorbital approach for tumors of the petroclival junction extending into the anterior cerebellopontine area
por: Lim, Jaejoon, et al.
Publicado: (2016)

Autologous adoptive immune-cell therapy elicited a durable response with enhanced immune reaction signatures in patients with recurrent glioblastoma: An open label, phase I/IIa trial
por: Lim, Jaejoon, et al.
Publicado: (2021)

NOX2-Induced High Glycolytic Activity Contributes to the Gain of COL5A1-Mediated Mesenchymal Phenotype in GBM
por: Park, Youngjoon, et al.
Publicado: (2022)

Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer
por: Hwang, Sohyun, et al.
Publicado: (2020)

Efficacy of Cytokine-Induced Killer Cell Immunotherapy for Patients With Pathologically Pure Glioblastoma
por: Han, Myung-Hoon, et al.
Publicado: (2022)

Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions
por: Jung, Daun, et al.
Publicado: (2021)

Natural killer cell immunotherapy in glioblastoma
por: Hosseinalizadeh, Hamed, et al.
Publicado: (2022)

Polymorphisms of Killer Ig-like Receptors and the Risk of Glioblastoma
por: Choi, Haeyoun, et al.
Publicado: (2023)

Re-Irradiation and Its Contribution to Good Prognosis in Recurrent Glioblastoma Patients
por: Kim, Mi Sun, et al.
Publicado: (2020)

miR-22-3p and miR-30e-5p Are Associated with Prognosis in Cervical Squamous Cell Carcinoma
por: Kwon, Ah-Young, et al.
Publicado: (2022)

Natural Killer Cell-Based Immunotherapy against Glioblastoma
por: Morimoto, Takayuki, et al.
Publicado: (2023)

T-Cell Receptor Repertoire Characteristics Associated with Prognostic Significance in High-Grade Serous Ovarian Carcinoma
por: Kim, Ju-Won, et al.
Publicado: (2023)

Natural Killer Cells and Immunotherapy
por: Noh, Ji-Yoon, et al.
Publicado: (2023)

Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in korea
por: Kong, Doo-Sik, et al.
Publicado: (2016)

Cytomegalovirus Infections after Hematopoietic Stem Cell Transplantation: Current Status and Future Immunotherapy
por: Cho, Sung-Yeon, et al.
Publicado: (2019)

The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma
por: Liu, Xudong, et al.
Publicado: (2023)

Association of Tim-3/Gal-9 Axis with NLRC4 Inflammasome in Glioma Malignancy: Tim-3/Gal-9 Induce the NLRC4 Inflammasome
por: Sim, JeongMin, et al.
Publicado: (2022)

CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma
por: Lupo, Kyle B., et al.
Publicado: (2020)

miR-150 enhances apoptotic and anti-tumor effects of paclitaxel in paclitaxel-resistant ovarian cancer cells by targeting Notch3
por: Kim, Tae Hoen, et al.
Publicado: (2017)

Clinical Applications of Immunotherapy for Recurrent Glioblastoma in Adults
por: Olivet, Meagan Mandabach, et al.
Publicado: (2023)

Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain
por: Lee, Se Jeong, et al.
Publicado: (2015)

Natural killer cell therapy potentially enhances the antitumor effects of bevacizumab plus irinotecan in a glioblastoma mouse model
por: Tran, Thi-Anh-Thuy, et al.
Publicado: (2023)

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

Immunotherapy for recurrent glioblastoma: practical insights and challenging prospects
por: Wang, Xin, et al.
Publicado: (2021)

Comparing the Expression of Canonical and Non-Canonical Inflammasomes Across Glioma Grades: Evaluating Their Potential as an Aggressiveness Marker
por: Kim, Yu Jin, et al.
Publicado: (2023)

Clinical Impact of microRNAs Associated With Cancer Stem Cells as a Prognostic Factor in Ovarian Carcinoma
por: Cha, So youn, et al.
Publicado: (2017)

Integrated analysis of microRNA-target interactions with clinical outcomes for cancers
por: Joung, Je-Gun, et al.
Publicado: (2014)

Tumor retractor: a simple and novel instrument for brain tumor surgery
por: Lim, Jaejoon, et al.
Publicado: (2020)

Chemical priming of natural killer cells with branched polyethylenimine for cancer immunotherapy
por: Choi, Seung Hee, et al.
Publicado: (2022)

Dramatic Response to Cabozantinib in a Patient with Refractory Hepatocellular Carcinoma with c-MET Amplification
por: Sang, Yun Beom, et al.
Publicado: (2023)

USP19 and RPL23 as Candidate Prognostic Markers for Advanced-Stage High-Grade Serous Ovarian Carcinoma
por: Kang, Haeyoun, et al.
Publicado: (2021)

Safety and immune cell kinetics after donor natural killer cell infusion following haploidentical stem cell transplantation in children with recurrent neuroblastoma
por: Choi, Young Bae, et al.
Publicado: (2019)

Natural Killer Cell Activity Test Helps to Suspect Aggressive Natural Killer Cell Leukemia - Diagnostic Challenge
por: You, Eunkyoung, et al.
Publicado: (2023)

GLIS1 in Cancer-Associated Fibroblasts Regulates the Migration and Invasion of Ovarian Cancer Cells
por: Kim, Mi Joung, et al.
Publicado: (2022)

Toll-Like Receptors in Natural Killer Cells and Their Application for Immunotherapy
por: Noh, Ji-Yoon, et al.
Publicado: (2020)

Branched multipeptide immunotherapy for glioblastoma using human leukocyte antigen-A*0201-restricted cytotoxic T-lymphocyte epitopes from ERBB2, BIRC5 and CD99
por: Kim, Young-Hee, et al.
Publicado: (2016)

Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma
por: Choi, Min Chul, et al.
Publicado: (2020)

Why is immunotherapy for glioblastoma “Lag”-ging
por: Mathios, Dimitrios, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h2blt6gm1c6ksq0ft0v8ltktbg